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IFN-α heteroduplex-tracking assay (IFN-HTA)king assay (IFN-HTA) was developed to quantify the frequency of expression of
the 16 genes coding for related interferon-α (IFN-α) subtypes in mice. In mLN of mice treated with Poly (I:
C), we observed the induction of three sequential waves of type I IFN production, instead of two as is
commonly described: early IFNs after 1 h (IFN-β), late IFNs after 3 h (mostly IFN-α1, -α2, -α4 and -α5) and
“secondary late IFNs” after 6 h (IFN-α6T and -α8/6). The late IFN wave was associated with the upregulation
of the interferon regulatory factor (IRF)-7 mRNA and proteins, whereas the secondary late IFN wave was
associated with a slight upregulation of IRF-8 mRNA. Type I IFNs produced in the thymus were associated
with a distinct IRF mRNA expression pattern. This IFN-HTA strategy can serve as a useful tool to qualify and
quantify the expression of various IFN-α subtypes under distinct immune responses and thus provides a ﬁrst
step in evaluating their function.
© 2009 Elsevier Inc. All rights reserved.Introduction
Type I Interferons constitute a heterogeneous group of proteins
that include interferon-alpha (IFN-α), IFN-β and the less-extensively
studied IFN-ɛ, IFN-κ, IFN-ω, IFN-δ and IFN-τ. IFN-α/β are inducible
cytokines that play a direct and crucial role in the early innate
response to viral infection. They both elicit antiviral activity that often
leads to the apoptosis of infected cells (Guidotti and Chisari, 2001;
Tanaka et al., 1998). Virus-induced IFN-α/β are also recognized for
their antiproliferative and immunomodulatory activities (Biron,
2001; Samuel, 2001).
A single IFN-β and 16 IFN-α subtype genes are encoded by an
intronless multigene family clustered on murine chromosome 4 (van
Pesch et al., 2004; van Pesch and Michiels, 2003). The multiplicity of
these genes which are conserved throughout vertebrate evolution has
remained a puzzle, especially since they share the same surface
receptor that appears to be coupled to a uniform signal transduction
cascade (Oritani et al., 2001). Following viral infections, the early
interferon genes IFN-β and IFN-α4 are expressed ﬁrst upon activation
of interferon regulatory factor-3 (IRF-3). IFN-β and -α4 proteins actentre de Recherche du CHUM,
.-P. Sékaly).
ll rights reserved.through a unique IFN-α/β receptor to induce IRF-7 expression. Finally,
late interferon genes—namely, IFN-α2, -α5, -α6T and -α8/6—are
expressed in response to an autocrine or paracrine feedback loop
mediated by IRF-7 (Levy et al., 2002; Marie et al., 1998; Sato et al.,
2000). Recent studies further support the hypothesis of differential
expression regulated at the cellular level by the IRF-5/IRF-7 ratio
(Barnes et al., 2003, 2001; Levy et al., 2003).
A key ﬁrst step to understanding the role of each subtype would
be to quantify them in response to different viral infections or stimuli.
However, IFN-α subtypes respectively share 85–93% and 78–89%
identity in their DNA and protein sequences, which results in the
absence of subtype-speciﬁc monoclonal antibodies. Although several
studies have conducted semi-quantitative RT-PCR using IFN-α
subtype-speciﬁc primers, several experiments are usually required
to generate conclusive results in a given single experiment (Fung
et al., 2004; Hughes et al., 1994). Another approach would consist in
sequencing multiple subclones derived by RT-PCR from consensual
IFN-α primers. However, such an approach would also require
considerable sequencing effort and would be subject to artefactual
detection of over-represented subtypes due to insufﬁcient IFN-α
transcript population sampling by PCR. To overcome these technical
limitations, we adapted the heteroduplex-tracking assay (HTA),
applicable to closely related sequences such as T-cell Receptors
(TCR) (Bernardin et al., 2003) to the IFN-α multigene family.
Fig. 1. Overview of the IFN-HTA strategy. SS: single stranded DNA, He: DNA hetero-
duplexes, Ho: DNA homoduplexes, as: antisense and s: sense.
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(dsRNA) is generated by many DNA and RNA viruses as a consequence
of viral replication, transcription or both. TLR3 is known to mediate
IFN-α/β production in response to natural and synthetic dsRNA,
including polyionosine-polycytidylic acid (Poly (I:C)) (Salio and
Cerundolo, 2005; Schroder and Bowie, 2005). TLR3s have been
implicated as receptors for numerous viruses, including mouse cyto-
megalovirus (MCMV), reovirus, inﬂuenza virus, respiratory syncytial
virus (RSV), Newcastle Disease Virus (NDV), rhinoviruses (RV), West
Nile virus (WNV), and simian immunodeﬁciency virus (SIV) (Guillot
et al., 2005; Hewson et al., 2005; Hoebe et al., 2003; Le Gofﬁc et al.,
2006; Prakash and Levy, 2006; Rehli, 2002; Rudd et al., 2005;
Sanghavi and Reinhart, 2005; Wang et al., 2004). Recently, a second
innate immunity system has been described, one that relies on the
cytoplasmic recognition of dsRNA by RNA helicases such as retinoic
acid inducible gene-I (RIG-I) or MDA5 (Helicard). Both share a similar
structural architecture and their expression, which is inducible by IFN
and viral infection, leads to the activation of NF-κB and IRF3 (for a
review, see (Honda and Taniguchi, 2006)).
In the present study, we administrated Poly (I:C) intra-peritoneally
(i.p.) to mice to induce high levels of IFN-α in vivo; we quantiﬁed each
subtype frequency using the IFN-HTA assay. In the mesenteric lymph
nodes (mLN) of treated mice, we found that expression of late IFNs
could be dissociated into two distinct and sequential waves of IFN-α
subtype expression.
Results
Overview of the IFN-HTA strategy
The IFN-α transcripts from thymus or lymph nodes of mice treated
with PBS or Poly (I:C) were ampliﬁed by PCR using primers
encompassing consensus sequences for all INF-α subtypes (see
Materials and methods), which resulted in a PCR mixture in which
all IFN-α subtype amplicons were present at their baseline concentra-
tions. This PCR IFN-α product was then mixed with a clonal, ﬂuo-
rescein-labeled HTA-probe, IFN-α2(s), for example, in Fig. 1. The mix
was then heated and cooled so that the DNA strands were ﬁrst
denatured and then re-annealed by nucleic acid complementarity. All
IFN-α molecules, whatever the subtype, will anneal with the HTA-
probe to form a DNA heteroduplex. Due to their partially double-
strand structures, DNA heteroduplexes can be electrophoretically
separated in native poly-acrylamide gel electrophoresis (PAGE).
Schematically, re-annealing a strand from an IFN-α subtype with a
high level of genetic heterogeneity with HTA-probe IFN-α2(s) leads to
the formation of a heteroduplex with numerous mismatches, as
illustrated for IFN-α2(s)/IFN-α4(as). The presence of these mis-
matches signiﬁcantly inhibited migration and reduced mobility
through PAGE. In contrast, re-annealing a strand from IFN-α subtypes
sharing a high level of genetic homogeneity with HTA-probe IFN-α2
(s) led to the formation of a heteroduplex with few mismatches. As
such, the migration of the subsequent heteroduplex was more com-
parable to the homoduplex, as illustrated for IFN-α2(s)/IFN-α1(as).
Furthermore, IFN-α subtype frequencies were proportional to the
heteroduplex band intensities, as shown for IFN-α2(s)/IFN-α1(as)
(Bernardin et al., 2003). Quantiﬁcation of each subtype's frequency
was performed with the Image-Quant software.
The combination of 4 HTA probes provides an assay that discriminates
the 16 different IFN-α subtypes
In a ﬁrst set of experiments, we assessed whether the range of
electrophoreticmobility of IFN-α heteroduplexes allowed their use for
HTA. We re-annealed the 16 puriﬁed subcloned IFN-α subtypes each
in pair-wise combinations with IFN-α11. The resulting heteroduplexes
were resolved by PAGE and ethidium bromide. As expected, IFN-αheteroduplexes generally displayed a mobility that was intermediate
between the homoduplex IFN-α11(s)/IFN-α11(as) and single-
stranded DNA (Fig. 2a). The same experiment was then performed
with probes IFN-α2, -α6T, -α8/6, -α14 and -αψ2. A wide mobility
range was obtained with all tested IFN-α probes, except for IFN-αψ2
(Fig. 2b). Interestingly, the IFN-αψ2 amplicon could be distinguished
by a 12-nucleotide deletion and displayed on average 16% hetero-
geneity with the other subtypes. These data strongly suggested that
IFN-HTA probes required a minimum of genetic homogeneity with
other IFN-α subtypes to be efﬁcient. From these results, mobility
ranges of IFN-α heteroduplexes allowed the use of HTA technology for
the discrimination of the 16 IFN-α subtypes.
We then sought to generate IFN-HTA probes. Amplicons of the 16
IFN-α subtypes were re-annealed in a pair-wise combination with
IFN-α2(as) HTA ﬂuorescent probe, and the resulting DNA hetero-
duplexes resolved by PAGE and scanned for ﬂuorescein (Fig. 2c). As
theoretically expected, only half of the initially IFN-α heteroduplexes
visualized with ethidium bromide was detected. Interestingly,
although IFN-α7/10(s), IFN-α9(s) and IFN-α14(s) sequences had
the same level of homology (88.55%) with IFN-α2, the resulting
heteroduplexes migrated differently as a result of nucleic acid
differences in their primary sequence. Two limitations appeared at
this step. First, the frequency of the IFN-α subtype used as an IFN-HTA
probe generated a ﬂuorescent homoduplex and thus could not be
isolated as well as the other subtypes (shown for IFN-α2, in Fig. 2c).
To overcome this limitation, we generated artiﬁcial IFN-HTA probes
resulting from PCR recombination with a short elongation time
(2 min). However, the IFN-HTA proﬁles obtained with artiﬁcial probes
showed lower resolution (data not shown). Second, although we
obtained a wide range of mobilities for the different amplicons, the
IFN-HTA proﬁles remained insufﬁcient to discriminate the 16
subtypes. In Fig. 2c, the migration patterns of IFN-α6T, -α8/6, -α9
and -α12 were hardly distinguishable. Therefore, we combined the
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(as) (Fig. 2d). With this combination, each IFN-α subtypewas isolated
at least once. When isolated several times (four times for IFN-αB), the
frequency measured was the mean of the values obtained with
distinct HTA probes. In conclusion, IFN-HTA provided a powerful tool
for discriminating the 16 IFN-α subtypes on the basis of their primary
structure.
IFN-HTA is more reproducible and sensitive than the cloning-sequencing
approach
The genetic sequence of an IFN-HTA probe is not expected to
inﬂuence its ability to anneal with other subtypes. Hence, we next
sought to conﬁrm that the genetic sequence and the ratio of IFN-HTA
probe/PCR product did not skew the measured values. The IFN-HTA
strategy was applied to quantify IFN-α subtypes in the thymus of
three mice since several IFN-α subtypes are expressed at low level in
lymphoid organs of healthy control mice (van Pesch and Michiels,
2003) (data not shown). In this experiment, different volumes of -α2
(s), -α8/6(as), -α11(as) and -α14(as) IFN-HTA probes were added to
20 μl PCR product: 2 μl (ratio=1/10), 5 μl (ratio=1/4), 10 μl
(ratio=1/2) and 20 μl (ratio=1) (Fig. 3a). None of the IFN-α subtype
frequencies was inﬂuenced by the concentration of the IFN-HTA
probe. Indeed, if we consider the values obtained with the four
concentrations of IFN-HTA probes, the frequency detected for each
subtype remained highly constant: IFN-α1 (7.7±0.8%), IFN-α2 (9.4±
0.4%), IFN-α4 (12.4±0.6%), IFN-α13 (1.5±0.6%), IFN-αA (10.6±
0.4%) and IFN-αB (3.8±0.4%). However, the genetic sequence of the
IFN-HTA probe impacted on the estimation of IFN-αB and IFN-α4. IFN-
αB frequencies were higher with probe IFN-α2(s). Additionally, IFN-
α4 measurement, which can be distinguished by a 15-nucleotide
deletion, was also inﬂuenced by the genetic sequence of IFN-HTA
probes. Nevertheless, these discrepancies were attenuated by the fact
that the calculated frequency was the average of values obtained with
the four different probes. For the IFN-HTA assay, a 1/2 ratio was used.
Finally, to assess the reproducibility of the assay, we re-investigated
the IFN-HTA-tested samples by the classical cloning/sequencing
approach. To achieve statistical signiﬁcance at least 30 clones were
analyzed for each thymus tested. Standard deviations for the two
approaches are shown in Fig. 3b, demonstrating the high reproduci-
bility of the IFN-HTA as compared to the cloning and sequencing
approaches. These experiments showed that IFN-HTA was not only
less time consuming, but also more reproducible than existing
techniques aiming at quantifying the expression of IFN α/β subtypes.
IFN-HTA easily detects variations in IFN-α subtype frequency
To quantitatively validate the IFN-HTA assay, we next examine if
we were able to detect variations in the frequency of IFN-α subtypes
that included different concentrations of plasmids encoding for a
speciﬁc panel of type I IFNs. The distribution of each type I IFN in the
different samples is described in Fig. 4. Subcloned IFN-α subtype
plasmids were mixed to generate three different samples: A, B and C.Fig. 2. The combination of 4 HTA probes provides an assay discriminating the 16
different IFN-α subtypes. PCR products issued from plasmid subclones of the 16 IFN-α
subtypes were mixed, denatured and re-annealed in pair-wise combinations with IFN-
α11 (a) or IFN-αψ2 (b) PCR products. The resulting DNA heteroduplexes were
resolved by PAGE and revealed by ethidium bromide. (c) PCR products issued from
plasmid subclones of the 16 IFN-α subtypes were mixed, denatured and re-annealed
in a pair-wise combination with IFN-α2(as) HTA probe. The resulting DNA
heteroduplexes were resolved by PAGE and scanned for ﬂuorescence. (d) PCR
products of the 16 IFN-α subtypes were pooled and the resulting samples were
mixed, denatured, re-annealed and scanned for ﬂuorescence with IFN-α2(s), IFN-α8/
6(as), IFN-α11(as) or IFN-α14(as) HTA probes. This combination of probes
discriminates all IFN-α subtypes. SS: single stranded DNA, He: DNA heteroduplexes,
Ho: DNA homoduplexes, as: antisense and s: sense.
Fig. 3. IFN-HTA is more reproducible and sensitive than cloning-sequencing approach. (a) IFN-HTA strategy was applied to thymus samples of untreated mice. For each HTA probe,
four concentrations were tested: the volume added to the 20 μl IFN-α PCR product was 2 μl (ratio HTA probe/PCR product=1/20), 5 μl (ratio=1/4), 10 μl (ratio=1/2) or 20 μl
(ratio=1). The results of 6 out of 16 subtypes are shown. Data represent themean and standard error for threemice. IFN-HTA (white squares) represents themean of the several HTA
probes. For example, the calculated IFN-α13 frequency was the mean of the frequencies obtained with IFN-α8/6(as), -α11(as) and -α14(as) probes. (b) Frequencies calculated with
the use of 10 μl of HTA probe were compared with data obtained with the classical cloning/sequencing approach. At least 30 clones were sequenced by thymus samples. Standard
errors for the two approaches are shown, demonstrating the high reproducibility of IFN-HTA.
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increased whereas IFN-α11 frequency decreased from sample A to C.
These variations were easily visualized on the gel when scanned for
levels of ﬂuorescein (Fig. 4a). All IFN-α subtype percentages
quantiﬁed with ImageQuant software were very similar to expected
values, with the exception of IFN-α4 which was overestimated (Fig.
4b, right panel). Similarly, the results showed high levels of IFN-α5
and -α14 frequencies when compared to the other subtypes (13%)
while IFN-α6T and -α9 were not detected in these samples. When
non-IFN-α4-subtype OD-measured frequencies were calculated as a
function of results obtained with the IFN-HTA, a strong correlation in
the two independent experiments performed (r=0.95, pb0.0001
Experiment 1, r=0.90, pb0.0001 Experiment 2) was shown (Fig. 4c).
Since IFN-α4 is rapidly produced in vivo during viral infections, it was
important to conﬁrm the capacity of measuring variations of this
particular subtype.Whenwe analyzed data obtained in Experiments 1
and 2 and integrated data from two other experiments, we also
obtained a strong correlation between IFN-HTA IFN-α4 measured
frequencies and known values (r=0.90, pb0.0001) (Fig. 4d). In
conclusion, the IFN-HTA constitutes a powerful tool for the detection
of the induction or inhibition of expression of all 16 IFN-α subtypes.
Poly (I:C) treatment induces three waves of IFN-α subtype expression
in mesenteric lymph nodes
The acute phase of viral infections is commonly associated with
heightened production of type I IFNs (Biron, 1998). In the current
study, we investigated the impact of Poly (I:C), a viral double-stranded
RNA (dsRNA) mimic, on the production of IFN-α subtypes. C57BL/6
mice were injected i.p. with 200 μg of Poly (I:C) and sacriﬁce occurred
1, 3, 6 or 12 h post-treatment. Type I IFN expressionwasﬁrstmonitored
by real-time PCR inmLN. Variable but signiﬁcant upregulation of IFN-β
mRNAs was observed 1 h post-treatment (Poly (I:C)/Uninfected:
1328.4±1163.1, PBS/Uninfected: 21.8±44.0, p=0.039) and rapidly
decreased to low levels after 6 h of Poly (I:C) treatment (Poly (I:C)/
Uninfected: 78.4±31.6, PBS/Uninfected: 32.7±45.3, p=0.0679)
(Fig. 5a). In contrast, in Poly (I:C) treated mice, a peak of IFN-α
production was detected at 3 h (Poly (I:C)/Uninfected: 42.5±14.1,
PBS/Uninfected: 1.0±0.6, p=0.0039), and remained high until 12 h
post-treatment (Poly (I:C)/Uninfected: 21.5±13.7, PBS/Uninfected:1.1±0.4, p=0.0062). Expression of low levels of IFN-α and -βmRNA
was observed in PBS treated mice (Démoulins et al., 2008). Of note, in
the present study, levels of IFNs induced in mice upon injection of PBS
are well below those observed upon administration of Poly (I:C) (11.5
(IFN-α(mLN)) and 12.8 (IFN-β(mLN)) fold less); we thus normalized
IFN-α and -β copy numbers in Poly (I:C) to PBS treated mice (Fig. 5b).
Mice administeredwith Poly (I:C) showed a 42-fold increase for IFN-α
at 3 h post-treatment and a 61-fold increase for IFN-β at 1 h post-
treatment. From these results, we could conﬁrm that Poly (I:C) was a
strong inducer of type I IFNs in lymphoid organs (Kuhara et al., 2006).
We then used the IFN-HTA assay to determine which IFN-α
subtypes were produced in lymph nodes from Poly (I:C) treated
mice. Gel proﬁles are shown in Fig 5c. Interestingly, qualitative
changes were visualized between the different time points. For
example, the signal band intensity for IFN-α4 clearly diminished
from 1 to 3 h post-treatment with all HTA-probes. Furthermore,
IFN-α subtypes absent in early time points were expressed 6 h
post-treatment. With the -α8/6(as) HTA-probe, for example, a low
signal was found 1 to 3 h post-treatment for 6T+11 band whereas
the band intensity clearly increased 6 h post-treatment. Further-
more, all IFN-α subtypes detected as early as 1 h post-treatment
remained detectable at later time points. The increased number of
subtypes produced over time post-treatment strongly suggested the
presence of a positive feedback loop mechanism. In Fig. 5d, the
signal intensities of the gel pattern are quantiﬁed with ImageQuant
software. IFN-α7/10 (0.7±0.3%), IFN-α13 (2.8±0.5%) IFN-αA (1.2±
0.3%) IFN-αB (1.3±1.4%)were also detected but not included in Fig. 5d
due to their low frequency. Only the frequency of IFN-α4 decreased
signiﬁcantly from 1 to 3 h post-injection of Poly (I:C) (1 h: 25.7±4.7%,
3 h: 10.5±1.0, p=0.000016), suggesting its early expression com-
pared to the other subtypes including IFN-α2 (1 h: 32.6±3.4%, 3 h:
30.0±2.5%, p=0.165).
We then quantitatively assessed kinetics of expression of the IFN-α
subtypes in Poly (I:C) treated mice by dividing the IFN-α total
levels with values obtained for each IFN-α subtype frequency (Fig.
5d): Σ (Mean RT-PCR IFN-α×IFN-HTA Mice a)+(Mean RT-PCR IFN-
α×HTA Mice b))/6 (Fig. 5e). IFN-α mRNA induction was
characterized by a peak in mRNA levels at 3 h post-treatment
included mostly IFN-α1, -α2 and -α5; IFN-α6T and 8/6 peaked at
6 h post-treatment (Fig. 5e). Finally, IFN-α4 expression was also
Fig. 4. IFN-HTA easily detects variations in IFN-α subtypes frequency. Concentrations of the 16 subcloned IFN-α subtypes were initially measured by optical density (OD) and
diluted at 1 ng/μl. These plasmids were then mixed in order to generate three different samples: A, B and C. For most subtypes, the concentration was constant from A to C: null
(IFN-α6T and -α9), 25 pg/μl (IFN-α1, -α2, -α7/10, -α8/6, -αB, -αψ2), 50 pg/μl (IFN-α3, -α13 and -αA), and 150 pg/μl (IFN-α5, -α14). In contrast, three subtypes were mixed with
a variable concentration from A, to, C samples: A: IFN-α4 (50 pg/μ), IFN-α11 (250 pg/μl) and IFN-α12 (25 pg/μl), B: IFN-α4 (95 pg/μl), IFN-α11 (120 pg/μl) and IFN-α12 (120 pg/
μl) and C: IFN-α4 (175 pg/μl), IFN-α11 (20 pg/μl) and IFN-α12 (210 pg/μl). L: ladder. PCR products of the 16 IFN-α subtypes were pooled and the resulting sample was mixed,
denatured, re-annealed as in Fig. 2d. (a) The resulting variations in frequency were easily visualized on the gel pattern, as indicated by the black arrows. (b) IFN-HTA calculated
frequencies (right panel) were compared to the deduced frequencies after dilution of plasmids measured by OD (left panel). Representative data from two independent
experiments are shown. (c) Values obtained with OD were calculated as a function of results obtained with IFN-HTA assay. (d) Values obtained with OD for IFN-α4 were calculated
as a function of values quantiﬁed with the IFN-HTA assay.
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results obtained with the IFN-HTA assay (Fig. 5f). A strong
correlation was found between these two independent experiments
(r=0.72, pb0.0001); real time PCR using speciﬁc IFN-α4 primers
gave similar results to what obtained using the IFN-HTA with a
peak observed at 3 h post Poly (I:C) treatment (1 h: 0.6±0.4 IFN-
α4/105 β-Actin; 3 h: 1.7±0.9 IFN-α4/105 β-Actin; p=0.044).
Taken together, these results demonstrate the presence of three
sequential waves of type I IFN expression following a dsRNAadministration: early IFNs after 1 h (IFN-β), late IFNs after 3 h
(mostly IFN-α1, -α2, α4 and -α5) and “secondary late IFN” after
6 h (IFN-α6T and -α8/6).
Poly (I:C) treatment induces a delayed and attenuated type I
IFN response within the thymus
We next analyzed whether the same IFN-α subtypes were prefe-
rentially expressed in the thymus (van Pesch et al., 2004) (Fig. 3).
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PCR compared to those observed in mLN. Indeed, although lower than
in LN (55-fold decrease 1 h post treatment), IFN-β mRNA induction
persisted over time (Fig. 6a). To a lesser extent, a slight IFN-α and -β
mRNA expression was observed in thymus of PBS treated mice;however, levels of IFNs induced in mice upon injection of PBS are below
those observed following the administration of Poly (I:C) (2.0 (IFN-
α(thymus)) and 2.0 (IFN-β(thymus)) fold less). We thus normalized
IFN-α and -β copy numbers in Poly (I:C) to PBS treated mice (Fig. 6b).
Once again, we found that Poly (I:C) treatment induced speciﬁcally
Fig. 6. Delayed and attenuated expression of IFN-α1, -α2 and -α5 in thymus following Poly (I:C) treatment. C57/BL6 mice were injected i.p. with 200 μg of Poly (I:C) or PBS control
solution and sacriﬁced 1, 3, 6 or 12 h post-treatment and thymuses were collected. (a) IFN-α and -β expressionwas quantiﬁed by real-time PCR. Six treated mice per group per time
point, normalized to quantiﬁcation in six untreated mice, are shown. (b) Normalization of IFN-α and -β copy numbers in Poly (I:C) to PBS treated mice. (c) IFN-HTAwas applied only
on Poly (I:C) and PBS treatedmice thymus 12 h post-treatment because the IFN-α absolute levels weremeasured at other time points. Gel patterns are shown for only half of themice
tested. L: ladder. PCR products of the 16 IFN-α subtypes were pooled and the resulting sample was mixed, denatured, re-annealed as in Fig. 2d. (d) This ﬁgure plots real time PCR IFN-
α absolute levels (panel a) by the IFN-HTA calculated frequencies (panel c), as described in Fig. 5e. (e) IFN-HTA was applied only on mLN, thymus and spleen samples of Poly (I:C)
treated mice 12 h post-treatment. The results are the average of six mice per group per time point.
231T. Démoulins et al. / Virology 386 (2009) 225–236type I IFNs: 5-fold increase for IFN-α at 3 h post-treatment; 7-fold
increase for IFN-β at 3 h post-treatment. IFN-HTA proﬁles appeared to
be very different between Poly (I:C) treated mice (mostly IFN-α1, -α2 -
α4, -α5 and -α11) and PBS treated mice (signals for at least nine IFN-αFig. 5. Poly (I:C) treatment leads to the expression of three waves of IFN-α subtypes in me
solution and sacriﬁced 1, 3, 6 or 12 h post-treatment. Mesenteric LNs were collected. (a) IFN
time point, normalized to quantiﬁcation in six untreated mice, are shown. (b) Normalizat
only applied on Poly (I:C) treated mice samples because the IFN-α absolute levels measure
(as) IFN-HTA gel patterns are represented. L: ladder. PCR products of the 16 IFN-α subtype
2d. (d) This ﬁgure shows the IFN-HTA calculated frequencies. Subtypes with frequencies l
errors for six mice per group per time point. (e) This ﬁgure plots real-time PCR IFN-α absolu
mice to obtain a quantitative kinetic of IFN-α subtypes: (Σ (Mean RT-PCR IFN-α×HTA M
three waves of type I IFNs occur following TLR-3 activation: early IFNs (IFN-β), late IFNs (I
obtained by RT-PCR with α4 speciﬁc primers were calculated as a function of values quansubtypes). Indeed, when IFN-α absolute levels (Fig. 6a) were plotted
by IFN-α subtype values (Fig. 6c), signiﬁcant differences were observed
for IFN-α1 (Poly (I:C): 24.5±4.5×10−5, PBS: 6.6±1.1×10−5,
p=0.000011), -α2 (Poly (I:C): 18.8±1.8×10−5, PBS: 7.5±2.2×10−5,senteric LN. C57/BL6 mice were injected i.p. with 200 μg of Poly (I:C) or PBS control
-α and -β expression was quantiﬁed by real-time PCR. Six treated mice per group per
ion of IFN-α and -β copy numbers in Poly (I:C) to PBS treated mice. (c) IFN-HTA was
d in panel a were too low in PBS treated mice. IFN-α2(s), -α8/6(as), α11(as) and -α14
s were pooled and the resulting sample was mixed, denatured, re-annealed as in Fig.
ower than three percent are not included. All data constitute the mean and standard
te level (panel a) by the IFN-HTA calculated frequencies (panel d) of Poly (I:C) treated
ice A)+(Mean RT-PCR IFN-α×HTA Mice B)…)/6. Schematically, from these results,
FN-α1, -α2, -α4 and -α5) and “secondary late IFNs” (IFN-α6T and -α8/6). (f) Values
tiﬁed with the IFN-HTA assay. ⁎pb0.05, ⁎⁎pb0.01.
232 T. Démoulins et al. / Virology 386 (2009) 225–236p=0.000007) and -α5 (Poly (I:C): 17.7±5.4×10−5, PBS: 5.3±
1.3×10−5, p=0.00077), which corroborated results obtained in
mLN (Fig. 6d). In contrast, IFN-α7/10 production was signiﬁcantly
reduced (Poly (I:C): 1.2±1.6×10− 5, PBS: 6.7±1.2×10− 5,
p=0.00012). Secondary late IFNs quantiﬁed 6 h post-treatment
in mLN remained undetectable 12 h post-treatment within the
thymus, suggesting that type I IFN response was distinct or at least
delayed in this compartment. We then applied the IFN-HTA strategy
to the spleens of these mice at 12 h post Poly (I:C) treatment to test
whether the type I IFN response was speciﬁc to each lymphoid
organ. Comparison of the abundance of the different IFN-α subtype
transcripts supported this hypothesis: levels of six IFN subtypes
were signiﬁcantly different between mLN and the thymus (i.e. p
(α1)=0.04754, p(α4)=0.02393, p(α11)=0.00019, p(α12)=
0.01184, p(α13)=0.03938 and p(αA)=0.02344) (n=6 in each
group) while levels of nine subtypes were signiﬁcantly different
between mLN and the spleen (i.e. p(α1)=0.00289, p(α4)=
0.00041, p(α6T)=0.00258, p(α7/10)=0.00023, p(α8/6)=0.00432,
p(α11)=0.00013, p(α12)=0.00006, p(α13)=0.04823 and p(αA)b
0.00001); ﬁnally frequencies of four subtypes were signiﬁcantly more
abundant in the thymus when compared to the spleen (i.e. p(α1)=
0.00010, p(α4)=0.00625, p(α12)=0.02395 and p(αA)=0.00646)
(Fig. 6e). Interestingly, IFN-α3, -α9, -α14 and -αψ2 were not detected
in any lymphoid organs. Since most of other subtypes were easily
detected (Fig. 4), the absence of detection of the latter subtypes was
not due to a technical limitation. In conclusion, although the same
subtypes were expressed, relative frequencies appeared to be signiﬁ-
cantly different between the distinct lymphoid organs. These distinct
expression proﬁles provide evidence of a highly regulated type I response
to dsRNA.
Distinct kinetics of type I IFN response are associated with speciﬁc
IRF proﬁle expression
IFN-α/β genes commonly possess regulatory cis-elements within
their promoters that bind to the members of transcription factors
IRFs (for a review see Honda and Taniguchi, 2006; Taniguchi et al.,
2001). We thus investigated whether early, late and secondary-late
type I IFN waves were associated with speciﬁc IRF-1, -5, -7, -8 or -9
expression patterns. This quantiﬁcation was performed with mLN
samples aliquoted from the IFN-α/β expression quantiﬁcation expe-
riment (Figs. 5 and 6). First, we could not observe any increase in
levels of expression of the different IRFs 1 h post-Poly (I:C) treatment
(Fig. 7a). These results are consistent with the current model
suggesting that the production of early IFNs results from the phos-
phorylation and translocation of available IRF-3 into the nucleus and
does not require the production of new IRF proteins (Levy et al.,
2002; Marie et al., 1998; Sato et al., 2000). Three hours post-
treatment, we observed a signiﬁcant increase in the expression of
IRF-1 (Poly (I:C): 2.89±1.03×10− 5, PBS: 0.79±0.13×10− 5,
p=0.00055), IRF-7 (Poly (I:C): 17.16±6.51×10−5, PBS: 0.96±
0.17×10−5, p=0.00012) and IRF-9 (Poly (I:C): 2.65±1.42×10−5,
PBS: 0.93±0.28×10−5, p=0.01577) mRNAs. These results also
agree with the current model suggesting that late IFNs are induced
in response to neo-transcribed IRF-7. We also found a signiﬁcant
increase in the expression of IRF-8 6 h post-treatment (Poly (I:C):
1.76±0.27, PBS: 1.24±0.25×10−5, p=0.0071). Finally, after 12 h
post-Poly (I:C) treatment, only IRF-7 and -9 remained expressed at
signiﬁcantly high levels (Fig. 7a).
The up-regulation of IRFs expressionwas then tested at the protein
level (Fig. 7b). Although we could detect signiﬁcant up-regulation of
IRF-1, -7 and -8 mRNAs, only IRF-7 was detected increased at the
protein level (Fig. 7c). Indeed, quantiﬁcation of 2 independent
experiments conﬁrmed the low or absent levels of IRF-8 production
in Poly (I:C) treated mice at the tested time points: 1 h (1.09-fold
increase), 3 h (1.00-fold increase) and 6 h (0.77-fold increase). Ofnote, IRF-7 mRNA induction (17.9-fold increase) was more important
than that of IRF-1 (3.6-fold increase) and IRF-8 (1.4-fold increase); the
absence of protein detection could be imputable to the lack of sen-
sibility of western blot approach. Also, discrepancies in the kinetics of
this upregulation were identiﬁed between IRF-7 mRNA (3 h post
treatment) and protein (1 h post treatment) kinetics of expression.
Overall, our results add to previous studies and show that ligation of
nucleic acid sensors of the innate immune system by Poly (I:C)
treatment is characterized by three sequential waves of type I IFNs
production : early IFNs (IFN-β after IRF-3 activation), late IFNs (IFN-
α1, -α2 and -α5 after IRF-7 mRNA induction/protein production) and
“secondary late IFNs” (IFN-α6T and -α8/6 after IRF-8 mRNA
induction).
We next investigated IRF expression proﬁles within the thymus,
where different type I IFNs responses were observed when
compared to mLN. Strikingly, all IRFs tested were upregulated 12 h
post-Poly (I:C) treatment: IRF-1 (Poly (I:C): 2.46±0.95×10−5, PBS:
0.85±0.20×10−5, p=0.00226), IRF-5 (Poly (I:C): 2.54±1.13×10−5,
PBS: 1.14±0.33×10−5, p=0.01557), IRF-7 (Poly (I:C): 11.61±
5.00×10−5, PBS: 0.93±0.95×10−5, p=0.00044), IRF-8 (Poly (I:C):
2.06±0.28×10−5, PBS: 1.03±0.26×10−5, p=0.02398) and IRF-9
(Poly (I:C): 7.94± 1.05×10−5, PBS: 1.21±0.56×10−5, pb0.00001)
(Fig. 7d). These results showed that distinct type I IFN kinetics were
associated with distinct IRF expression patterns when comparing
mLN and the thymus.
Discussion
In the present study, we have developed the IFN-HTA assay, a
powerful tool to quantify the relative expression of the 16 IFN-α
subtypes in C57BL/6 mice. This tool was shown to be highly
reproducible, valid and more efﬁcient than existing techniques for
measuring variations in IFN-α subtype frequencies. We thus asso-
ciated the IFN-HTA assay with the quantiﬁcation of the absolute levels
of type I IFNs mRNAs by RT-PCR. When applied to mLN of Poly (I:C)
treated mice at different time points post-treatment, three successive
waves of type I IFN production (instead of two as currently accepted)
were detected: early IFNs after 1 h post-treatment (-β), late IFNs after
3 h post-treatment (mostly -α1, -α2 and -α5), and “secondary late
IFNs” after 6 h post-treatment (-α6T and -α8/6). Late IFNs were
associated with the upregulation mRNA and protein of the transcrip-
tion factor IRF-7 whereas the “secondary late IFNs” were associated
with the upregulation of IRF-8mRNA. In the thymus, type I IFNsmRNA
expression of Poly (I:C) treated mice was delayed and associated with
a distinct IRF expression pattern.
Poly (I:C) mimics a virally-encoded TLR ligand—dsRNA—shown to
interact mostly with TLR3 but can also interact with other nucleic acid
binding effector molecules of innate immunity such as RIG-I and
MDA-5 (Honda et al., 2006; Salio and Cerundolo, 2005; Schroder and
Bowie, 2005). Although pDCs represent the major source of type I
IFNs, they minimally express TLR-3, suggesting another source of type
I IFN production in the lymphoid organs in Poly (I:C) treated mice
(for a review see (Asselin-Paturel and Trinchieri, 2005; Colonna et al.,
2004)). Of note, myeloid DCs and macrophages are present in mLN
and thymus, and they express TLR-3. It is thus likely that these cell
types are the major source of the locally-produced type I IFNs we
observed in lymphoid organs of Poly (I:C) treated mice (Anjuere et
al., 1999; Takahama, 2006). A second, recently-described innate
immune sensor relies on the cytoplasmic recognition of dsRNA by
RNA helicases such as retinoic acid inducible gene-I (RIG-I) or MDA5
(Helicard). Both share a similar structural architecture, and their
expression, which is inducible by IFN and viral infection, leads to the
activation of NF-κB and IRF3 (for a review, see Honda and Taniguchi,
2006). Altogether, these data raise the importance of the cell types
studied for the analysis of type I IFN responses. The conclusions of the
differential expression of type I IFN subtypes can only be limited to
Fig. 7. Distinct kinetics of type I IFN response are associated with speciﬁc IRF proﬁle expression. C57/BL6 mice were injected i.p. with 200 μg of Poly (I:C) or PBS control solution and
sacriﬁced 1, 3, 6 or 12 h post-treatment and mLN and thymuses were collected. (a) Upregulation of IRF expression in mLN of Poly (I:C) treated mice as a function of time. The results
are the average of six mice per group per time point. First, all individual mice values were obtained by subtracting the calibrator sample value (mice treated with PBS and sacriﬁced
1 h post-treatment) from their raw data. Second, all individual Poly (I:C) treatedmice values were divided by the average of the related control group (6mice treated with PBS). (b, c)
IRF-1, -3, -5, -7 and -9 western blot scans are shown (c), as well IRF-3 and -7 protein levels (band quantiﬁcation) 3 h after post-treatment. Western blot results are representative of
two independent experiments. PIC: Poly (I:C). Importantly, IRF-9 antibody was not available for this experiment (d) Upregulation of IRF expression in the thymus of Poly (I:C) treated
mice at 12 h post-Poly (I:C) treatment. Data are presented as the average of 5–6 mice per group per time point. ⁎pb0.05, ⁎⁎pb0.01.
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expression proﬁles.
Type I IFNs are produced in the absence of viral infections (albeit
at low levels) both in vitro and in vivo. A weak IFN-α/β signal could
be crucial for predisposing cells to enhance their response to other
stimuli (revving-up model) (for a review, see (Honda et al., 2006;
Honda and Taniguchi, 2006)). In line with these data, we were able
to detect low levels of IFN-α, including early and late subtypes in the
thymus of untreated C57BL/6 mice, demonstrating that they can be
constitutively produced at low levels (Fig. 5a). Constitutive tran-
scription of IFN-α/β has previously been reported in both thymii
and lymph nodes and in speciﬁc cell types (Gessani et al., 1991; Hata
et al., 2001; Hida et al., 2000; Montoya et al., 2002; Nickolaus and
Zawatzky, 1994; Zawatzky et al., 1991). Using a cloning-sequencing
approach, Van Pesch et al. demonstrated that several IFN-α subtypeswere transcribed at higher frequencies in lymphoid organs (spleen
and thymus) of uninfected Ifnar−/− mice. In addition, IFN-α13 is
constitutively expressed in murine L929 ﬁbroblasts; however, the
biological function(s) and the kinetics of induction of this subtype
remain unknown (van Pesch and Michiels, 2003). Finally, Hata et al.
(2001) have shown that IFN-α transcription in uninfected Ifnar−/−
mouse embryonic ﬁbroblasts (MEFs) occurred at levels comparable
to levels observed in uninfected WT cells. Altogether, these data
conﬁrm our observation that type I IFN transcription occurs at low
levels in basal conditions independently of the IFNα/β signaling
pathway.
IFN-α/β genes commonly possess regulatory cis-elements within
their promoters that bind to the members of the IRF family of
transcription factors (for a review see Honda et al., 2006; Honda and
Taniguchi, 2006; Taniguchi et al., 2001). Currently, there are ten
234 T. Démoulins et al. / Virology 386 (2009) 225–236members within the mammalian IRF family (IRFs 1 to 10), all of which
contain a conserved DNA binding domain. Since IRF-1, IRF-3, IRF-5,
IRF-7, IRF-8 and IRF-9 have been implicated in the transcriptional
induction of the IFN-α/β genes (Barnes et al., 2003; Mamane et al.,
1999; Sato et al., 2000; Tailor et al., 2006), expression of these factors
were ﬁrst tested in mLN of Poly (I:C) treated mice. Schematically, type
I IFN subtypes expression is described as a biphasic IFNs mRNA
induction: early IFNs depend on IRF-3 activation (IFN-α4 and IFN-β)
and late IFNs depend on IRF-7 production (IFN-α2, -α5, -6T and -8/6)
(Levy et al., 2002; Marie et al., 1998; Sato et al., 2000; van Pesch et al.,
2004). In i.p. Poly (I:C) treated mice, we conﬁrmed that expression of
IFN-βwas the earliest IFN to be induced , whereas IFN-α4, displayed a
peak of expression only at 3 h post-treatment.
Although we found early and late IFNs respectively 1 and 3 h post-
treatment, our results added another level of complexity. Indeed, we
could dissociate late IFNs (IFN-α1, -α2, -α4 and -α5) from “secondary
late IFNs” (IFN-α6Tand -8/6) after 6 h post-Poly (I:C). This third set of
type I IFN subtypes was expressed at low levels, and their expression
persisted until 12 h post-treatment. Interestingly, the IFN-α6T gene
lacks a functional IRF-7 binding site, conﬁrming that the induction of
this particular subtype depends on other transcription factor(s) and is
thus different from classical late IFNs (van Pesch et al., 2004).
Moreover, we showed that IFN-α6T and -α8/6 mRNA expression was
associated with the increased expression of IRF-8 mRNAs (Fig. 7a).
Interestingly, a recent study reported the occurrence of a late peak of
IFNs mRNA in bone marrow derived pDC and cDC 7 h post infection of
mice with Newcastle Disease Virus (NDV) infection. This peak was
abrogated in IRF-8−/−mice, demonstrating the importance of this IRF
in the induction of the late set of IFN-α subtypes (Tailor et al., 2006)
(Tailor et al., 2007). IRF-1 and IRF-9 exhibited a similar proﬁles of
expression when compared to IRF-7, though the fold increase of IRF-1
and IRF-9 was lower in C57BL/6 mice treated with Poly (I:C) than
that observed with IRF-7. Discrepancies in the kinetics of upregula-
tion of IRF-7 mRNA (3 h. post treatment) and protein (1 h post
treatment) could be attributed to the fact that two distinct sets of
Poly (I:C) treated mice were used to perform these assessments.
Moreover stability of IRF7 protein from spleen and thymus has been
reported to be considerably reduced when compared to MEFs, with a
predicted half-life of 1–2 h. This very low IRF-7 stability in this
speciﬁc context could also explain these differences (Prakash and
Levy, 2006). Overall, these observations support the notion of a
redundant impact of IRFs or the induction of type I IFNs (Matsuyama
et al., 1993). We found no differences in levels of IRF-5 mRNA
expression when comparing Poly (I:C) and PBS treated mice,
suggesting that this IRF is not associated with the induction of
type I IFN in mLN. When coupled with earlier conﬂicting studies,
these data reveal the need for further investigations to clarify
whether TLR3 directly activates IRF-5 and whether IRF-5 contributes
to IFN-α subtype induction (Barnes et al., 2001; Schoenemeyer et al.,
2005; Takaoka et al., 2005). The discrepancies between our results
and previous reports could also be explained by the technical
limitations used by these groups (cloning sequencing and subtype
speciﬁc primer RT-PCR) and by the fact that we explored IFN
producing cells within mLN. The kinetics of IFN-α subtypes was
delayed in the thymus since secondary late IFNs were undetected
until 12 h post-treatment. Interestingly, these differences were asso-
ciated with a distinct IRF expression panel characterized by the
increased expression of IRF-1, IRF-5, IRF-7, IRF-8 an IRF-9. We cannot
exclude, however, that type I IFN production in the thymus might
result from systemically produced type I IFNs rather than the direct
effect of Poly (I:C) in a subset(s) of cells in the thymus.
Conclusions
By applying an IFN-HTA assay, we have demonstrated the occur-
rence of 3 sequential waves of type I IFN production in mLN after Poly(I:C) treatment: early IFNs after 1 h (IFN-β), late IFNs after 3 h (mostly
IFN-α1, -α2, -α4 and -α5) and “secondary-late IFNs” after 6 h (IFN-
α6Tand -α8/6). The quantitative differences observed as a function of
time and lymphoid organs raise the importance of the diversity of the
IFN-α response and each subtype's precise role. In conclusion, the IFN-
HTA strategy can serve as a useful ﬁrst step in the analysis of the
various IFN-α subtypes' expression in various immune responses and,
as such, to evaluate their respective contribution to a protective or
deleterious immune response.
Materials and methods
Mouse studies
Four- to six-week-old female C57BL/6 mice were purchased from
the Charles River Laboratory. Mice were injected once with Poly (I:C)
(200 μg per injection in PBS, (Invivogen)) or with PBS intra-peritoneal
(i.p.) and sacriﬁced 1 to 12 h post-treatment. Importantly, Poly (I:C)
was certiﬁed LPS-free by the manufacturer. After sacriﬁce, thymus and
mesenteric lymph nodes (mLN) were isolated, disrupted, treated for
10 min with collagenase D (Roche) and prepared as single-cell
suspensions. Our animal studies were approved by the local regu-
latory committee (CIPA).
RNA extraction and cDNA synthesis
Total cellular RNA from10×106 cells obtained from thymus ormLN
was puriﬁed using the RNeasy mini-kit (QiaGen, Valencia, CA),
according to the manufacturer's protocol, and followed by the
addition of 20 U of RNAse inhibitor (Roche Diagnostic, Indianapolis,
IN) and DNase I digestion. First-strand cDNA synthesis used 1–2 μg
RNA, 1.5 μg of six-nucleotide-long random primers (Life Technologies,
Rockville, MD) and 200 U of M-MLV reverse transcriptase (Gibco BRL
Life technologies, Rockville, MD) at 37 °C for 50 min in a ﬁnal volume
of 42 μl, according to the manufacturer's instructions.
Analysis of the sequences of the 16 IFN-α transcripts
IFN-α PCR was carried out for respectively 35 and 45 cycles in
mesenteric lymph nodes and the thymus with the use of consensual
primers: IFN-α sense 5′-ATGGCTAGRCTCTGTGCTTTCCT-3′, IFN-α
antisense 5′-AGGGCTCTCCAGAYTTCTGCTCTG-3′. Amplicons were
ligated into the pCR 4-TOPO vector and introduced into Escherichia
coli (Invitrogen, The Netherlands). Positive clones were sequenced
with the dRhodamine terminator cycle-sequencing ready-reaction
kit (Applied Biosystems) and nucleotide sequences were deter-
mined with a sequencer (Applied Biosystems). To exclude the risk of
sample contamination, PCR mixes and PCR ampliﬁcations/cloning
were carried out in separate rooms. We carried out these
experiments simultaneously for all the samples tested. Lastly, we
used van Pesch et al.'s (2004) nomenclature for the IFN-α subtype
analysis.
IFN-α heteroduplex-tracking assay (IFN-HTA)
We ﬁrst established PCR ampliﬁcation conditions to avoid PCR
recombination among IFN-α subtypes (35–45×94 °C 30 s, 60 °C 30s
and 72 °C 10 mn). IFN-HTA probes were generated by PCR in 100 μl
reaction volume from 100 ng of puriﬁed subcloned IFN-α subtype
using one of the two consensual primers (sense or antisense) coupled
with ﬂuorescein (Invitrogen, Montreal, Ca). The mixture of the HTA
probe and target was denatured for 3 min at 95 °C using a
thermocycler and directly cooled on ice. DNA heteroduplexes were
separated on 16 cm high, 1.5 mm thick, 4% stacking and 8%
polyacrylamide gels in 1× TBE at 150 V for 30 min (pre-run) and
200 V for 6 h. IFN-HTA gels were scanned for ﬂuorescein with a
Table 1
Gene Primer A Primer B Probe
IRF-1 TGGAGATGTTAGCCCGGACACTTT ACGGTGACAGTGCTGGAGTTATGT ACCTGATGACCACAGCAGTTACACCA
IRF-5 CTGATGATTACGTTCTGGGAGA GTTGGGAGGCCCAGGTAG UPL #63 (04688627001)
IRF-7 CCAGACTGCCTGTGTAGACG AGCCAGTCTCCAAACAGCAC UPL #41 (04688007001)
IRF-8 GAGCCAGATCCTCCCTGACT GGCATATCCGGTCACCAGT UPL #26 (04687574001)
IRF-9 GGATGTTGCTGAACCCTACAA CTGGTTCCGTGGTTGGTTAG UPL #18 (04686918001)
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and quantiﬁed with ImageQuant analysis 5.1 software (Molecular
Dynamics). ImageQuant allows for a densitometric quantitation of
each heteroduplex band's signals. As such, a subtype's frequency can
be calculated as the percentage of this particular transcript among all
members of the IFN-α multigene family.
IFN-α and IFN-β real time PCR analysis
cDNAwas used as template in the quantitative PCRmix according to
the manufacturer's standard protocol (Roche). The primer sequences
were: IFN-α sense (s) 5′-GCTAGGCHYTRTGCTTTCCT-3′, IFN-α anti-
sense (as) 5′-CACAGRGGCTGTGTTTCTTC-3′, IFN-β (s) 5′-TTCAAGTG-
GAGAGCAGTTGAG-3′, IFN-β (as) 5′-CATCAACTATAAGCAGCTCCA-3′
(Marie et al., 1998) IFN-α4 (s) 5′-GCTTTCCTCATGATCCTAGTAA-3′,
IFN-α4 (as) 5′-AGGAGGTTCCTGCATCACA-3′ and β-Actin (s) 5′-
CGTACCACAGGCATTGTGA-3′, β-actin (as) 5′-CTCGTTGCCAATAGT-
GATGA-3′. Quantiﬁcations were made by means of SYBR Green
ﬂuorochrome. The speciﬁcity of RT-PCRwas controlled by no template
and no RT controls. PCR efﬁciencies for all reactions were determined
and were similar. Threshold values were normalized to the expression
of β-actin. Quantitative PCR results were expressed relative to the
induction of the housekeeping gene β-actin (1/2Ct).
IFN regulatory factor (IRFs) quantiﬁcation analysis
IRF-5, -7, -8 and -9 gene expression levels were determined using
primer and probe sets from Universal ProbeLibrary (https://www.
roche-applied-science.com) (Table 1). Custom primer and taqMan
probes of IRF-1 were designed using the online version of the
PrimerQuest software (http://scitools.idtdna.com/Primerquest/).
PCR reactions for 384 well plate formats were performed using 2 μl
of cDNA samples (50 ng), 5 μl of the TaqMan PCR Master Mix (Applied
Biosystems, CA), 2 μM of each primer and 1 μM of the Universal
TaqMan probe in a total volume of 10 μl. The ABI PRISM® 7900HT
Sequence Detection System (Applied Biosystems) was used to detect
the ampliﬁcation level and was programmed to an initial 10-minute
step at 95 °C, followed by 40 15-second cycles at 95 °C and 1 min at
60 °C. All reactions were run in duplicate and the average values were
used for quantiﬁcation. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and β-actin were used as endogenous controls. The relative
quantiﬁcation of target genes was determined by using the ΔΔCT
method. Brieﬂy, the Ct (threshold cycle) values of target genes are
normalized to an endogenous control (ec) (ΔCT=Cttarget−Ctec) and
compared with a calibrator (PBS-treated mice 1 h post treatment):
ΔΔCT=ΔCtSample−ΔCtCalibrator. The relative expression (RQ) of each
mouse was calculated using the Sequence Detection System (SDS)
2.2.2 software (Applied Biosystems) and the formula RQ=2−ΔΔCT.
Western blotting
Western blotting was performed as previously described (Riou
et al., 2007). The following polyclonal rabbit anti-Interferon
Regulatory Factors (IRFs) antibodies were used: anti-IRF-1 (1/
100, Cell Signaling Technology), anti-IRF-3 (1/625, Cell Signaling
Technology), anti-IRF-5 (1/200, Cell Signaling Technology), anti-
IRF-7 (1/625, Santa Cruz Biotechnology, inc) and anti-IRF8 (1/100,Santa Cruz Biotechnology, inc). The monoclonal mouse anti-β-actin
antibody (1/2500; clone AC-15; Sigma-Aldrich) was also used as a
protein load control.
Statistical analysis
Data are expressed as means±s.e.m. Statistical signiﬁcance of
differences was determined by the paired two-tailed Student t-test
(IFN-α subtype's frequencies and IRFs quantiﬁcation) and the non-
parametric Mann Whitney test (IFN-α and -β quantiﬁcation). In the
latter case, MannWhitney test was considered more appropriate than
Student t-test as high inter-individual animal variations do not allow
the assumption of a normal distribution. Differences were considered
statistically signiﬁcant for: ⁎pb0.05, ⁎⁎pb0.01. Statistical analyses
were performed using Excel software (Microsoft).
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